Glaxosmithkline Pharmaceuticals Ltd (GLAXO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 793005, "name": "Glaxosmi. Pharma", "stock_name": "Glaxosmi. Pharma", "full_name": "Glaxosmithkline Pharmaceuticals Ltd", "name_url": "stocks-analysis/glaxosmi-pharma", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "2,484.70", "chg": 5.75, "chgp": "0.23%", "dir": 1, "prev_price": "2,478.95", "mcapval": "41,405.00 Cr", "mcap": "Mid Cap", "scripcode": 500660, "symbol": "GLAXO", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE159A01016", "curr_date": "May 08", "curr_time": "", "bse_nse_vol": "1.19 lacs", "exc_status": "Active", "traded_date": "May 08, 2026", "traded_date_str": "2026 05 08", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glaxosmi-pharma-793005-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3972085", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/Glaxosmithkline_mojoScore_3972085.png", "date": "2026-05-01 10:10:29", "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing." }, { "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3953815", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/Glaxosmithkline_mojoScore_3953815.png", "date": "2026-04-20 10:10:48", "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3939384", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/Glaxosmithkline_mojoScore_3939384.png", "date": "2026-04-09 10:10:32", "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing." }, { "title": "Glaxosmithkline Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Returns", "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-market-returns-3938723", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/Glaxosmithkline_technicaldot_3938723.png", "date": "2026-04-09 08:04:24", "description": "Glaxosmithkline Pharmaceuticals Ltd has experienced a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a modest day gain of 1.04%, the stock’s technical indicators present a complex picture, reflecting mixed signals across weekly and monthly timeframes. Investors and analysts are closely monitoring these developments as the mid-cap pharmaceutical player navigates a challenging market environment." }, { "title": "Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade", "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-faces-bearish-momentum-amid-technical-downgrade-3933755", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/Glaxosmithkline_technicaldot_3933755.png", "date": "2026-04-06 08:01:52", "description": "Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The company’s recent downgrade from a Hold to a Sell rating by MarketsMOJO, accompanied by a Mojo Score of 43.0, reflects growing concerns over its near-term price performance amid a challenging market environment." }, { "title": "Glaxosmithkline Pharmaceuticals Gains 2.27%: Technical Challenges and Market Resilience", "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-gains-227-technical-challenges-and-market-resilience-3932085", "imagepath": "", "date": "2026-04-04 16:00:03", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>30 Mar:</strong> Stock hits 52-week low of Rs.2,218 amid bearish momentum</p>\n <p><strong>30 Mar:</strong> Mojo Grade downgraded to Sell reflecting technical weakness</p>\n <p><strong>1 Apr:</strong> Stock rebounds with a 1.79% gain, outpacing Sensex</p>\n <p><strong>2 Apr:</strong> Minor correction of 0.60% on subdued volume</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2,283.40</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">R..." }, { "title": "Markets Rally, But Glaxosmithkline Pharmaceuticals Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off", "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-falls-to-52-week-low-of-rs2218-3925143", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_priceRelatedfactors_3925143.png", "date": "2026-03-30 13:56:11", "description": "Despite a broader market rebound, Glaxosmithkline Pharmaceuticals Ltd has slipped to a fresh 52-week low of Rs 2,218 on 30 Mar 2026, extending its recent downward trajectory amid sector-wide volatility and company-specific valuation concerns." }, { "title": "Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade", "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-faces-bearish-momentum-amid-technical-downgrade-3923410", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_technicaldot_3923410.png", "date": "2026-03-30 08:02:06", "description": "Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening momentum, underscoring challenges ahead for investors in this mid-cap pharmaceutical stock." }, { "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3921542", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_mojoScore_3921542.png", "date": "2026-03-28 10:10:03", "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook." } ], "total": 5174, "sid": "793005", "stock_news_url": "https://www.marketsmojo.com/news/glaxosmithkline-pharmaceuticals-793005" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation", "datetime": "07-May-2026", "details": "Analyst Meet on 13th May 2026", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "22-Apr-2026", "details": "Publication of special window for share transfer and Saksham Niveshak Campaign", "source": "BSE" }, { "caption": "Board Meeting Intimation for Audited Financial Results (Standalone & Consolidated) For The Year Ended 31St March 2026 And Dividend If Any", "datetime": "22-Apr-2026", "details": "Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2026 inter alia to consider and approve Audited Financial Results (Standalone & Consolidated) for the year ended 31st March 2026 and dividend if any", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "", "data": [ { "title": "BOARD MEETING", "txt": "13 May 2026" } ] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Glaxosmithkline Pharmaceuticals Ltd has declared <strong>420%</strong> dividend, ex-date: 30 May 25", "dt": "2025-05-30", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Glaxosmithkline Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Sep 18", "dt": "2018-09-11", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

30 Mar: Stock hits 52-week low of Rs.2,218 amid bearish momentum

30 Mar: Mojo Grade downgraded to Sell reflecting technical weakness

1 Apr: Stock rebounds with a 1.79% gain, outpacing Sensex

2 Apr: Minor correction of 0.60% on subdued volume

Read full news article

Markets Rally, But Glaxosmithkline Pharmaceuticals Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off

2026-03-30 13:56:11

Despite a broader market rebound, Glaxosmithkline Pharmaceuticals Ltd has slipped to a fresh 52-week low of Rs 2,218 on 30 Mar 2026, extending its recent downward trajectory amid sector-wide volatility and company-specific valuation concerns.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-03-30 08:02:06

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening momentum, underscoring challenges ahead for investors in this mid-cap pharmaceutical stock.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-03-28 10:10:03

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article